COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that a scientific study evaluating the key attributes of Cartiform® will be presented at the 2014 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, March 11-15, in New Orleans, Louisiana. C. Thomas Vangsness, Jr., MD, Professor of Orthopedic Surgery at USC's Keck School of Medicine and Chief of Sports Medicine at University Hospital will present the findings of the study.
Cartiform is a viable cartilage mesh available at point-of-care designed for augmentation of microfracture or marrow stimulation procedures. The allograft matrix is designed to optimize interactions with mesenchymal stem cells from the bone marrow for articular cartilage repair and chondrogenesis. The unique properties of Cartiform for cartilage repair were characterized by examining the cellular organization within the extracellular matrix through histological analysis. Preservation of the three-dimensional architecture found in native articular cartilage was confirmed through the identification of extracellular matrix and cells organized into superficial, transitional and radial zones. The study includes in vitro laboratory and in vivo animal model data.
“Given our unique knowledge of mesenchymal stem cell science and over 20 years of experience, Osiris has the opportunity to enhance current treatment options and outcomes for orthopedic and sports medicine injuries,” said Michelle LeRoux Williams, Ph.D., Chief Scientific Officer. “We are looking to provide clinicians and patients with products that will successfully support the natural repair of damaged articular cartilage.”
Dr. Vangsness is scheduled to present on the Characterization of A Novel Viable Cartilage Mesh For Microfracture Augmentation For Focal Chondral Defects on Tuesday, March 11th at 9:42 a.m. CT (10:42 a.m. ET). AAOS is the preeminent provider of musculoskeletal education to orthopaedic surgeons and its annual meeting is the largest orthopaedic meeting in the world. Visit Osiris at AAOS Booth 6528.
About Osiris Therapeutics
Osiris Therapeutics, Inc. is the leading stem cell company, having developed the world’s first approved stem cell drug, remestemcel-L for graft versus host disease. Osiris’ products include Grafix® and Ovation® for acute and chronic wounds, Cartiform, a viable cartilage mesh for cartilage repair and the latest addition to Osiris’ line of products, OvationOS™, a viable bone matrix. Osiris is a fully integrated company with capabilities in research, development, manufacturing and distribution. Osiris has developed an extensive intellectual property portfolio to protect the company's technology and commercial interests.
Osiris, Grafix, Ovation and Cartiform are registered trademarks of Osiris Therapeutics, Inc. More information can be found on the company's website, www.Osiris.com. (OSIR-G)
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "ongoing," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: our product development efforts; our clinical trials and anticipated regulatory requirements, and our ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our product and product candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy for marketed Biosurgery products (including Grafix, Ovation, OvationOS and Cartiform) and Biosurgery products under development; our cash needs; patents, trademarks and other proprietary rights; the safety and ability of our products and potential products to address medical needs; our ability to supply a sufficient amount of our marketed products or product candidates and, if approved or otherwise commercially available products, to meet demand; our costs to comply with governmental regulations; our plans for sales and marketing; our plans regarding facilities; types of regulatory frameworks we expect will be applicable to our products and potential products; and results of our scientific research. Additional risks and uncertainties related to the sale of our ceMSC assets and the related transactions contemplated by the Purchase Agreement with Mesoblast include typical business transactional risks, the risk of changing relationships with customers, suppliers or employees, the risk associated with the disposition of our ceMSC assets and the increased relative dependence on and importance of our other business including our Biosurgery business, the risk that we may not be able to fully benefit from the transactions through milestone payments or royalties, payment risks, including the risk associated with receipt of equity as consideration, in lieu of cash, and the risk of dependence on others to achieve results upon which milestone or royalty payments to us are conditioned. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled "Risk Factors" in our Annual Report on Form 10-K and other Periodic Reports filed on Form 10-Q, with the United States Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.
